Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603 203, Chengalpattu (Dt), Tamil Nadu, India.
Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603 203, Chengalpattu (Dt), Tamil Nadu, India.
Curr Neurovasc Res. 2023;20(3):296-313. doi: 10.2174/1567202620666230721111144.
There has been a protracted effort to identify reliable targets for migraine. It is believed that each year, hundreds of millions of individuals worldwide suffer from migraines, making this widespread neurological ailment the second leading cause of years of disability worldwide. The rationale of this study is to identify the major targets involved in migraine attacks.
For this review, specialized databases were searched, such as PubMed, EMBASE, DynaMed Plus, and Science Direct databases that included the pathophysiological mechanisms of migraine, focusing on in vitro and in vivo studies in the clinical management of migraine.
Calcitonin gene-related peptide, Pituitary adenylate cyclase-activating polypeptide (PACAP), NOD-like receptor Protein (NLRP3), Serotonin, and some other neuroinflammatory biomarkers are collectively responsible for the cerebral blood vessel dilation and involved in the nociceptive pain which leads to migraine attack.
Migraine biomarkers such as CGRP, PACAP, NLRP3, Nitric oxide synthase, MMP9, and Serotonin could be targets for developing drugs. Present marketed medications temporarily reduce symptoms and pain and have serious cardiovascular side effects. It is suggested that herbal treatment may help prevent migraine attacks without adverse effects. Natural biomolecules that may give better treatment than the present marketed medication and full fledge research should be carried out with natural biomarkers by the Network Pharmacological approach.
长期以来，人们一直在努力寻找可靠的偏头痛靶点。据信，全世界每年有数亿人患有偏头痛，这种广泛存在的神经疾病是全球致残的第二大主要原因。本研究的目的是确定偏头痛发作涉及的主要靶点。
本综述检索了专门的数据库，如 PubMed、EMBASE、DynaMed Plus 和 Science Direct 数据库，其中包括偏头痛的病理生理机制，重点是偏头痛临床管理中的体外和体内研究。
降钙素基因相关肽、垂体腺苷酸环化酶激活肽 (PACAP)、NOD 样受体蛋白 (NLRP3)、血清素和其他一些神经炎症生物标志物共同导致脑血管扩张，并参与导致偏头痛发作的伤害性疼痛。
偏头痛生物标志物，如 CGRP、PACAP、NLRP3、一氧化氮合酶、MMP9 和血清素，可能成为开发药物的靶点。目前上市的药物只能暂时缓解症状和疼痛，且具有严重的心血管副作用。建议使用草药治疗可能有助于预防偏头痛发作，且没有不良反应。应该通过网络药理学方法，利用天然生物标志物进行更好的治疗效果的全方面研究。
